KALA BIO, Inc. (KALA) Dividend History

Company News

• KALA BIO Announces Chief Executive Officer Transition

  KALA BIO, Inc. announced the resignation of its CEO Mark Iwicki and the appointment of Todd Bazemore as interim CEO. Iwicki will continue to serve as Chair of the Board. Bazemore has over 30 years of experience in the pharmaceutical industry and will lead the company as it approaches topline data from the ongoing Phase 2b clinical trial of its lead product candidate KPI-012 for the treatment of persistent corneal epithelial defect (PCED).

  GlobeNewswire Inc.
• KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

  KALA BIO, a clinical-stage biopharmaceutical company, announced that its Head of R&D and Chief Medical Officer will present at the Piper Sandler 36th Annual Healthcare Conference. The company is focused on developing innovative therapies for rare and severe eye diseases.

  GlobeNewswire Inc.
• KALA BIO to Present at Jefferies Global Healthcare Conference

  ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 5, 2024.

  GlobeNewswire Inc.
• Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?

  The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  Zacks Investment Research
• KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

  -- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

  GlobeNewswire Inc.